Stifel starts Lexeo at buy, cites ataxia and Alzheimer’s drug candidates (LXEO)
ismagilov Stifel has started coverage of newly public Lexeo Therapeutics (NASDAQ:LXEO) with a buy rating, saying it was bullish on ...
ismagilov Stifel has started coverage of newly public Lexeo Therapeutics (NASDAQ:LXEO) with a buy rating, saying it was bullish on ...
© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.
© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.